Summary

U.S. Point Of Care DOA Testing Market Summary

The U.S. point of care drug of abuse (DOA) testing market size was estimated at USD 370.55 million in 2024 and is projected to grow at a CAGR of 9.3% from 2025 to 2033. The market is driven by an increasing need for rapid and on-site drug testing across multiple settings. Point-of-care DOA tests, which include urine, saliva, and occasionally blood-based panels, are widely used in workplaces, emergency departments, law enforcement, rehabilitation centers, and schools. These tests offer immediate results, helping healthcare professionals and institutions make faster decisions related to patient care, compliance, and risk mitigation. Their portability and ease of use are further increasing their adoption among non-laboratory professionals, contributing to market penetration.

One of the primary market drivers is the escalating incidence of drug abuse in the U.S., particularly related to opioids, cannabis, cocaine, and amphetamines. According to the National Center for Drug Abuse Statistics, over 20 million Americans aged 12 and older had a substance use disorder in 2023. This rising trend has heightened the demand for efficient drug screening tools, particularly in emergency and occupational health settings. Additionally, increased funding from federal agencies such as SAMHSA (Substance Abuse and Mental Health Services Administration) and state-level opioid response programs has bolstered the adoption of rapid testing tools.

Mandates for pre-employment, random, and post-incident drug testing in safety-sensitive industries such as transportation, construction, and healthcare are significantly contributing to market growth. The U.S. Department of Transportation (DOT) and other regulatory bodies have stringent requirements that compel employers to implement DOA screening protocols. POC testing is especially valued in these settings for its ability to quickly identify intoxication or recent drug use, helping mitigate legal liability and ensure workforce safety.

U.S. Point of Care Drug of Abuse Testing Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. point of care drug of abuse (DOA) testing market report based on product, sample type, technology, and end-use:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Immunoassay Test Strips and Cassettes
• Oral Fluid Testing Kits
• Breath Analyzers
• Urine Collection Cups
• Digital/Portable Analyzers
• Sample Type Outlook (Revenue, USD Million, 2021 - 2033)
• Urine
• Saliva (Oral Fluid)
• Breath
• Blood
• Sweat/Hair
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Lateral Flow Assay (LFA)
• Chromatographic Immunoassays
• Enzyme-linked Immunosorbent Assay (ELISA)
• Mass Spectrometry (Portable or Hybrid POC Units)
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Emergency Departments
• Workplace & Occupational Health Center
• Home Care & Remote Users
• Others

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. U.S. Point of Care Drug of Abuse (DOA) Testing Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.1.1. Rising substance abuse rates and opioid crisis
3.3.1.2. Increased adoption in workplace and law enforcement
3.3.1.3. Shift toward non-invasive and rapid testing methods
3.3.2. Market Restraints Analysis
3.3.2.1. Stringent Regulations
3.3.3. Market Opportunities Analysis
3.3.4. Market Challenges Analysis
3.3.4.1. Product Recalls
3.4. U.S. Point of Care Drug of Abuse (DOA) Testing Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
Chapter 4. U.S. Point of Care Drug of Abuse (DOA) Testing Market: Product Estimates & Trend Analysis
4.1. U.S. Point of Care Drug of Abuse (DOA) Testing Market: Product Movement Analysis
4.2. U.S. Point of Care Drug of Abuse (DOA) Testing Market Estimates and Forecasts, by Product (USD Million), 2024 & 2033
4.3. Immunoassay Test Strips and Cassettes
4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4. Oral Fluid Testing Kits
4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Breath Analyzers
4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Urine Collection Cups
4.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. Digital/Portable Analyzers
4.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. U.S. Point of Care Drug of Abuse (DOA) Testing Market: Sample Type Estimates & Trend Analysis
5.1. U.S. Point of Care Drug of Abuse (DOA) Testing Market: Sample Movement Analysis
5.2. U.S. Point of Care Drug of Abuse (DOA) Testing Market Estimates and Forecasts, by Sample (USD Million), 2024 & 2033
5.3. Urine
5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4. Saliva (Oral Fluid)
5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Breath
5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Blood
5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. Sweat/Hair
5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. U.S. Point of Care Drug of Abuse (DOA) Testing Market: Technology Estimates & Trend Analysis
6.1. U.S. Point of Care Drug of Abuse (DOA) Testing Market: Technology Movement Analysis
6.2. U.S. Point of Care Drug of Abuse (DOA) Testing Market Estimates and Forecasts, by Technology (USD Million), 2024 & 2033
6.3. Lateral Flow Assay (LFA)
6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4. Chromatographic Immunoassays
6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Enzyme-Linked Immunosorbent Assay (ELISA)
6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Mass Spectrometry (portable or hybrid POC units)
6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. U.S. Point of Care Drug of Abuse (DOA) Testing Market: End Use Estimates & Trend Analysis
7.1. U.S. Point of Care Drug of Abuse (DOA) Testing Market: End-use Movement Analysis
7.2. U.S. Point of Care Drug of Abuse (DOA) Testing Market Estimates and Forecasts, by End-use (USD Million), 2024 & 2033
7.3. Hospitals & Emergency Departments
7.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4. Workplace & Occupational Health Center
7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Home Care & Remote Users
7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Others
7.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.5. Company Profiles/Listing
8.5.1. Abbott
8.5.1.1. Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Quest Diagnostics Inc
8.5.2.1. Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Thermo Fisher Scientific
8.5.3.1. Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. OraSure Technologies
8.5.4.1. Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Siemens Healthineers
8.5.5.1. Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. F. Hoffmann-La Roche Ltd.
8.5.6.1. Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Drägerwerk AG & Co. KGaA
8.5.7.1. Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Premier Biotech
8.5.8.1. Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. American Screening Corporation, Inc.
8.5.9.1. Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. Aegis Sciences Corporation
8.5.10.1. Overview
8.5.10.2. Financial Performance
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives
8.5.11. MP Biomedicals
8.5.11.1. Overview
8.5.11.2. Financial Performance
8.5.11.3. Product Benchmarking
8.5.11.4. Strategic Initiatives
8.5.12. Innovacon (Alere, Abbott)
8.5.12.1. Overview
8.5.12.2. Financial Performance
8.5.12.3. Product Benchmarking
8.5.12.4. Strategic Initiatives